Le Lézard
Classified in: Health, Science and technology
Subject: MISCELLANEOUS

Nass Valley Gateway Ltd. Announces It Will File Its 2022 EOY Audited Financials and 2022 Annual MD&A Reports by June 30th, 2023, and Within the Extension Granted by the BCSC


VANCOUVER, BC, May 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire ? Nass Valley Gateway Ltd. (CSE:NVG) (OTC:NSVGF)(FSE:3NVN)(the "Company"), and its management announces it continues to work closely with its auditor (BF Borgers CPA PC) to fulfill the specific requirement of filing its EOY 2022 Financials, MD&A report and all attending certifications. Per the submitted plan, NVG will file these requirements by June 30th, 2023, or before, and within the extension provided by the BCSC.

Management has satisfied the alternative information guidelines by publishing this bi-weekly update and will continue to do so until the filing is completed.

There are no material changes or other items to report at this time.

ABOUT NASS VALLEY GATEWAY LTD. 

Nass Valley Gateway Ltd. (CSE: NVG) (OTC: NSVGF) (FSE: 3NVN)

Nass Valley Gateway LTD. (NVG) is a publicly traded company on the CSE in the Life Sciences category. Nass Valley Gateway Ltd., via its subsidiary Nass Valley Gardens Inc., is focused on the sales and distribution of organic, non-GMO hemp-based, CBD products. NVG CBD products are sold under the "Nass Valley Gardens" brand via retail and digital sales channels. NVG's products target the pain remediation, dermatology, sleep, anti-aging, and beauty markets.

We seek Safe Harbor.

Neither the CSE nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of the contents of this news release.

Company: Nass Valley Gateway Ltd.
422 Richards Street, Suite 170
V6B 2Z4 Vancouver
Canada

Contact: Michael Semler
Phone: 609-651-0032
E-mail: [email protected]
Internet: www.nassvalleygateway.com




These press releases may also interest you

at 14:20
The global gastroesophageal reflux disease (GERD) market  size is estimated to grow by USD 879.8 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  3.2%  during the forecast period.  Rising geriatric...

at 12:48
Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distribution agreement with Ascendis Pharma A/S ("Ascendis"), a global biopharmaceutical company headquartered in Copenhagen, Denmark. Under the terms of...

at 12:36
Imperial Tobacco Canada Limited ("ITCAN") has officially submitted its feedback to Health Canada regarding the proposed Ministerial Order on nicotine replacement therapy products (NRTs). ITCAN strongly believes that NRTs, especially innovative...

at 12:20
The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented...

at 12:10
The "Diagnostic Imaging Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Diagnostic Imaging Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...

at 12:05
King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of...



News published on and distributed by: